Business Context and Reporting Period
Cormedix Inc. (CRMD) filed a Current Report on Form 8-K dated September 20, 2019. The filing addresses a material definitive agreement regarding the amendment of Series B Warrants originally issued in a public offering closed on May 3, 2017.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on the terms of a warrant amendment.
Material Changes
On September 20, 2019, the Company amended Series B Warrants held by specific investors. Key details include:
- Warrant Scope: The amendment covers warrants representing the right to purchase up to 1,224,263 shares of common stock.
- Original Terms: The warrants were issued with an exercise price of $5.25 per share.
- Amendment Provision: The amendment adds a provision allowing the Company, with the consent of the Holder, to voluntarily reduce the exercise price of the Series B Warrant.
- Current Status: As of the filing date, the Company has not reduced the exercise price of any Holder's warrant.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on operations, or a discussion of general risks. The Company noted that if it elects to reduce the exercise price of a Holder's warrant in the future, it intends to file an additional Form 8-K to disclose such reduction.
Investor Verification Checklist
- Verify the total number of Series B Warrants outstanding and the portion subject to the amendment (1,224,263 shares).
- Confirm the current exercise price remains at $5.25 per share as no reduction has been executed.
- Review Exhibit 10.1 for the specific legal language governing the voluntary price reduction mechanism.
- Monitor future filings for any announcements regarding the actual exercise of the price reduction option.